T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1026
DoubleVerify
DV
$2.04B
| $23M | ﹤0.01% |
2,012,780
-54,567
| -3% | -$602K |
|
1027
Build-A-Bear
BBW
$474M
| $23M | ﹤0.01% |
374,756
+211,145
| +129% | +$11.5M |
|
|
SNCY
1028
DELISTED
Sun Country Airlines
SNCY
| $22.8M | ﹤0.01% |
1,587,181
+387,520
| +32% | +$4.95M |
|
1029
Markel Group
MKL
$22.8B
| $22.8M | ﹤0.01% |
10,605
+514
| +5% | +$1.04M |
|
1030
Biohaven
BHVN
$2.24B
| $22.8M | ﹤0.01% |
2,018,550
+8,939
| +0.4% | +$111K |
|
1031
Jacobs Solutions
J
$16.8B
| $22.8M | ﹤0.01% |
171,774
-3,482
| -2% | -$511K |
|
|
QXO
1032
QXO Inc
QXO
$16.1B
| $22.8M | ﹤0.01% |
1,179,335
+296,208
| +34% | +$5.68M |
|
1033
Immunovant
IMVT
$8.64B
| $22.7M | ﹤0.01% |
893,056
+688,472
| +337% | +$15.4M |
|
1034
Invitation Homes
INVH
$18B
| $22.7M | ﹤0.01% |
815,747
-61
| -0% | -$1.7K |
|
1035
Turning Point Brands
TPB
$1.73B
| $22.6M | ﹤0.01% |
208,397
+606
| +0.3% | +$59.3K |
|
1036
Fox Class A
FOXA
$27.5B
| $22.5M | ﹤0.01% |
308,116
-28
| -0% | -$1.83K |
|
1037
Freshworks
FRSH
$3.51B
| $22.5M | ﹤0.01% |
1,837,527
-264,453
| -13% | -$3.12M |
|
1038
Infosys
INFY
$50.3B
| $22.4M | ﹤0.01% |
1,259,618
-344,651
| -21% | -$5.96M |
|
1039
XPO
XPO
$24.7B
| $22.4M | ﹤0.01% |
164,907
+5,726
| +4% | +$780K |
|
1040
Zoom
ZM
$32.2B
| $22.4M | ﹤0.01% |
259,080
-36,890
| -12% | -$3.11M |
|
1041
Alpha Metallurgical Resources
AMR
$1.97B
| $22.3M | ﹤0.01% |
111,526
+1,328
| +1% | +$230K |
|
1042
Universal Health Services
UHS
$10.1B
| $22.3M | ﹤0.01% |
102,049
-8,725
| -8% | -$1.93M |
|
1043
Procept Biorobotics
PRCT
$1.26B
| $22.2M | ﹤0.01% |
705,740
-169,441
| -19% | -$5.62M |
|
1044
Vital Farms
VITL
$498M
| $21.6M | ﹤0.01% |
676,454
+5,519
| +0.8% | +$194K |
|
1045
Bausch + Lomb
BLCO
$6.06B
| $21.5M | ﹤0.01% |
1,260,306
+23,340
| +2% | +$370K |
|
1046
Super Micro Computer
SMCI
$25.3B
| $21.2M | ﹤0.01% |
724,255
-2,765
| -0.4% | -$114K |
|
1047
Rigetti Computing
RGTI
$6.21B
| $20.5M | ﹤0.01% |
924,254
-3,909,881
| -81% | -$127M |
|
|
RERE
1048
ATRenew
RERE
$1.02B
| $20.4M | ﹤0.01% |
3,857,684
+1,450,764
| +60% | +$6.5M |
|
1049
Valvoline
VVV
$4.31B
| $19.8M | ﹤0.01% |
681,597
+126,379
| +23% | +$4.06M |
|
1050
Kinross Gold
KGC
$31.9B
| $19.8M | ﹤0.01% |
702,891
+322,948
| +85% | +$8.39M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.